Key result
MMP-2 showed 93.3% sensitivity and TGF-β showed 90% specificity for diagnosing hypertrophic cardiomyopathy, correlating with clinical remodeling parameters.
Why the study?
Dysregulation of MMPs, TIMPs, and profibrotic cytokines is reported in HCM and linked to adverse remodeling, but relationships among these biomarkers and clinical outcomes required investigation.
Does the measurement of extracellular matrix biomarkers (MMPs, TIMPs, TGF-β, PIIINP) improve the identification of patients with hypertrophic cardiomyopathy?
Does the measurement of extracellular matrix biomarkers (MMPs, TIMPs, TGF-β, PIIINP) improve the identification of patients with hypertrophic cardiomyopathy?
MMP-2 and TGF-β demonstrate high sensitivity and specificity, respectively, suggesting their potential utility as diagnostic biomarkers for hypertrophic cardiomyopathy.
Should not yet change HCM diagnostic practice; leaves open biomarker utility pending prospective validation.
Significant dysregulation of matrix metalloproteinase (MMPs), their tissue inhibitors (TIMPs) and profibrotic cytokines have been reported in hypertrophic cardiomyopathy (HCM) and associated with adverse cardiac remodeling. We aim to investigate the relationship among MMPs, TIMPs, transforming growth factor-β (TGF-β) and amino terminal propeptide of type III procollagen (PIIINP) in HCM patients, and to explore their associations with clinical outcomes. We recruited 46 HCM patients and 49 controls, and measured biomarkers levels using ELISA. Receiver operating characteristic (ROC) analysis revealed the highest diagnostic sensitivity for MMP-2 (93.3%) and specificity for TGF-β (90%). Significant correlations were found between biomarkers and clinical parameters, including interactions between TGF-β and left ventricular mass, MMP-2 and intraventricular septum, PIIINP and maximal wall thickness. We suggest that TGF-β, with the highest specificity and MMP-2, with high sensitivity, may offer significant potential for identifying patients with HCM and serve as useful biomarkers for this disease.
No takes yet. Share an insight, caveat, or question.
Fourti et al. (2026) studied this question. MMP-2 showed 93.3% sensitivity and TGF-β showed 90% specificity for diagnosing hypertrophic cardiomyopathy, correlating with clinical remodeling parameters.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: